Investment Analysts’ Recent Ratings Updates for Acrivon Therapeutics (ACRV)

by · The Cerbat Gem

A number of research firms have changed their ratings and price targets for Acrivon Therapeutics (NASDAQ: ACRV):

  • 12/22/2025 – Acrivon Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
  • 12/21/2025 – Acrivon Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
  • 12/15/2025 – Acrivon Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
  • 12/13/2025 – Acrivon Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
  • 12/8/2025 – Acrivon Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
  • 12/1/2025 – Acrivon Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/25/2025 – Acrivon Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
  • 11/22/2025 – Acrivon Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
  • 11/19/2025 – Acrivon Therapeutics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.

Recommended Stories